{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1234.50",
  "meta": {
    "versionId": "10",
    "lastUpdated": "2022-01-06T01:02:20.000-05:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.50",
  "version": "20220106",
  "name": "COVID19 vaccine codes for exposure identification",
  "status": "active",
  "date": "2022-01-06T01:02:20-05:00",
  "publisher": "BEST System Steward",
  "compose": {
    "include": [
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.42"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.44"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.43"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75"
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:8518849c-72bb-4c63-adb0-13a5071069ba",
    "timestamp": "2022-06-10T06:39:20-04:00",
    "total": 28,
    "offset": 0,
    "parameter": [
      {
        "name": "count",
        "valueInteger": 1000
      },
      {
        "name": "offset",
        "valueInteger": 0
      }
    ],
    "contains": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0001A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0002A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0003A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0011A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0012A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0013A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "0031A",
        "display": "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, single dose"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "207",
        "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "208",
        "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "210",
        "display": "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "212",
        "display": "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "213",
        "display": "SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "217",
        "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "218",
        "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system": "http://hl7.org/fhir/sid/cvx",
        "version": "20220412",
        "code": "219",
        "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "code": "2468235",
        "display": "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "code": "2470234",
        "display": "SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "code": "2479835",
        "display": "SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "code": "2583743",
        "display": "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "91300",
        "display": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "91301",
        "display": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "code": "91303",
        "display": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW013S6",
        "display": "Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW013T6",
        "display": "Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW013U6",
        "display": "Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW023S6",
        "display": "Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW023T6",
        "display": "Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "code": "XW023U6",
        "display": "Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6"
      }
    ]
  }
}